Skip to main content
Clinical Trials/NCT03813017
NCT03813017
Unknown
Not Applicable

Comprehensive Assessment of Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis

Ziv Hospital0 sites100 target enrollmentOctober 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiovascular Diseases
Sponsor
Ziv Hospital
Enrollment
100
Primary Endpoint
Cardiovascular disease risks in patient with theumatoid arthritis
Last Updated
6 years ago

Overview

Brief Summary

Cardiovascular disease is a leading cause for morbidity and mortality in general population. The incidence of cardiovascular disease and their poor outcome is well documented in a broad spectrum of connective tissue diseases, especially in rheumatoid arthritis (RA). The risk of incident CVD is increased by 48% in patients with RA compared to the general population.

RA is associated with 50% increase in the mortality in patients with cardiovascular disease (CVD). One reason is the more frequent cardiovascular risk factors in RA patients compared with the general population. Patients with RA have a high risk of premature cardiovascular disease (CVD). The aim of the present study is to assess whether there are non-invasive measures that might predict arteriosclerosis in RA patients.

Registry
clinicaltrials.gov
Start Date
October 2019
End Date
July 2020
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Ziv Hospital
Responsible Party
Principal Investigator
Principal Investigator

Osamah Hussein

Head of Internal Medicine A

Ziv Hospital

Eligibility Criteria

Inclusion Criteria

  • 18-70 years old (except for women till 75 years old)
  • Absence of established CVD:
  • Myocardial Infarction p/h
  • PCI with balloon and/or stent
  • Intermittent claudication
  • PAD / intervention
  • CAS /intervention
  • Signed informed consent form
  • Documented diagnosis of rheumatoid arthritis

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Cardiovascular disease risks in patient with theumatoid arthritis

Time Frame: 6 months

Prediction of cardiovascular risks and proposed preventive treatment

Similar Trials